PACE Phosphonoacetate vs BNA in Gapmer ASOs: Mechanism, RNase H Activity, and Antisense Applications

In a gapmer ASO, PACE phosphonoacetate and BNA are doing completely different jobs even though both improve antisense performance.

A gapmer has two functional regions:

[ wing ] - [ DNA gap ] - [ wing ]

• Wings = affinity/stability region
• Gap = RNase H activation region

The goal is:

• bind RNA strongly
• recruit RNase H
• cleave target RNA

BNA in a gapmer

BNA (often LNA-type chemistry) is usually placed in the wings.

Example: BNA-BNA-BNA-DNA-DNA-DNA-DNA-BNA-BNA-BNA

What BNA does

BNA mainly improves:

• RNA binding affinity
• target specificity
• nuclease resistance
• duplex stability

The bridged sugar locks the nucleotide into the RNA-binding conformation.

Effect:

• much higher melting temperature (Tm)
• tighter RNA binding
• longer target occupancy

Why BNA is NOT usually in the gap

RNase H recognizes:

• a relatively natural DNA/RNA duplex

Too much BNA:

• distorts geometry
• prevents RNase H cleavage

So:

• BNA mainly stays in the wings
• DNA stays in the center gap

PACE phosphonoacetate in a gapmer

PACE modifies the backbone linkage, not the sugar.

Instead of:

phosphodiester

you get:

phosphonoacetate linkage

This changes:

• charge distribution
• backbone flexibility
• protein interactions
• nuclease susceptibility
• pharmacokinetics

What PACE does

PACE mainly improves:

• metabolic stability
• in vivo behavior
• biodistribution
• toxicity profile
• serum persistence

It is more of a drug-like behavior optimization.

Key difference

BNA controls TARGET BINDING

Think: “Grab RNA harder.”

BNA affects:

• duplex thermodynamics
• affinity
• specificity

PACE controls BACKBONE BEHAVIOR

Think: “Make the oligo survive and distribute better.

” PACE affects:

• PK
• stability
• protein binding
• tolerability

In a gapmer specifically

RNase H compatibility difference

This is the most important mechanistic point.

BNA effect on RNase H

Too much BNA:

• makes duplex too RNA-like or too rigid
• RNase H activity drops

Therefore:

• BNA confined to wings
• DNA gap preserved

This is the classic “gapmer architecture.”

PACE effect on RNase H

PACE changes the backbone chemistry.

Depending on:

• number of PACE linkages
• position
• spacing

RNase H may:

• tolerate it
• partially tolerate it
• lose activity

So PACE requires careful optimization.

Backbone modifications are more delicate for RNase H recruitment than wing modifications.

Current usage

BNA/LNA gapmers

Very established.

Common architecture:

• phosphorothioate backbone
• LNA/BNA wings
• DNA core

This is clinically validated.

PACE gapmers

More experimental/platform engineering.

Used to:

• reduce toxicity
• tune distribution
• improve therapeutic index

Less universally adopted than LNA gapmers.

Simplified analogy

BNA

Like upgrading the “grip” of the ASO.

The ASO sticks to RNA much harder.

PACE

Like upgrading the “body armor” and pharmacology of the ASO.

The ASO survives longer and behaves better in vivo.

Conclusion:

In gapmer ASOs:

• BNA is primarily an affinity-enhancing wing chemistry

• PACE phosphonoacetate is primarily a backbone/PK optimization chemistry

BNA improves:

• potency
• specificity
• RNA binding

PACE improves:

• stability
• biodistribution
• tolerability
• pharmacokinetics